* To assess the safety and tolerability of single and multiple ascending intravenous doses of AAI101 (SAD \& MAD) in healthy male subjects. * To assess the safety and tolerability of single and multiple ascending intravenous doses of AAI101 in combination with fixed intravenous doses of piperacillin or cefepime in healthy male subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
56
600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
Vehicle infusion
piperacillin 3 g i.v.
Safety Profile - Number of Subjects With at Least one Adverse Event
Safety will be evaluated from reported signs and symptoms and clinical laboratory tests
Time frame: Throughout the period that subjects receive study drug up to 5 days following discontinuation of study treatment
AAI101 maximum plasma concentration (Cmax)
Cmax will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin
Time frame: Up to 24 hours post-dose
AAI101 Clast
Clast will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin
Time frame: Up to 24 hours post-dose
AAI101 AUC(0-t) - AUC(0-8)
AAI101 Urea Under the Curve will be compared before and after administration of AAI101 either alone or in the presence of cefepime or piperacillin
Time frame: Up to 24 hours post-dose
AAI101 half life (t1/2)
AAI101 t1/2 plasma pharmacokinetic parameter will be compared for AAI101 alone or in the presence of cefepime or piperacillin
Time frame: Up to 24 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
cefepime 1 g i.v.